查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1877432

勃起功能障碍市场：依应用、治疗类型、产品类型、配销通路、国家及地区划分－全球产业分析、市场规模、市场占有率及2025-2032年预测

Erectile Dysfunction Market, By Application, By Therapy Type, By Product Type, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 397 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年，勃起功能障碍市场规模价值 25.6787 亿美元，从 2025 年到 2032 年，复合年增长率为 8.2%。

勃起功能障碍（ED）是指持续无法达到或维持足以进行满意度生活的勃起状态。它是一种多因子疾病，由血管、神经、荷尔蒙或心理因素引起，对男性的身心健康产生重大影响。心血管疾病和糖尿病等慢性疾病在全球范围内的日益流行，以及久坐不动的生活方式和压力相关疾病，都是导致ED的重要因素，也是推动市场发展的关键因素。然而，威而钢和希爱力等重磅药物专利到期，导致价格下降和仿製药的激烈竞争，从而限制了市场发展。儘管如此，新一代口服疗法、干细胞疗法以及提供线上咨询和处方服务的数位健康平台的开发，为市场带来了新的机会。这些创新，加上人们越来越认识到性健康是男性健康的重要组成部分，有望推动勃起功能障碍市场的长期成长和现代化。

勃起功能障碍市场－市场动态

生活方式相关疾病盛行率上升将推动市场成长

生活方式相关疾病的日益普遍预计将推动勃起功能障碍市场的发展。生活型态相关疾病是指主要由不良习惯（例如饮食不健康、缺乏运动、吸烟和酗酒）所引起的健康问题。生活方式相关疾病的增加归因于久坐行为的增加、不良饮食习惯、压力以及吸烟和过量饮酒等不良习惯。勃起功能障碍（ED）是心血管疾病和糖尿病等生活方式相关疾病的早期预警信号，凸显了及时就医和选择更健康生活方式的重要性。例如，根据总部位于英国的非营利组织世界肥胖联盟于2022年5月发布的报告，到2030年，全球将有10亿人肥胖，其中包括五分之一的女性和七分之一的男性；到2035年，肥胖人口将增至40亿，占全球人口的51%。因此，生活方式相关疾病的日益普遍将推动勃起功能障碍行业的成长。

勃起功能障碍市场細項分析：

全球勃起功能障碍市场按应用、治疗类型、产品类型、配销通路和地区进行细分。

根据该申请，由于希爱力（Cialis）、Stendra、威而钢（Viagra）等口服药物的使用量增加（这些药物可自行服用且经济实惠），以及市场参与者之间合作与伙伴关係的加强，预计到2025年，口服药物将成为全球勃起功能障碍药物市场中收入最高的细分市场。例如，2022年5月，Laboratorios Rubio SA将处方药BANDOL（西地那非口服悬浮液）出售给了Aspargo Laboratories, Inc.。 BANDOL用于治疗勃起功能障碍。同时，Aspargo与Rubio签署了一项分销协议，继续在西班牙市场销售和推广BANDOL。

按配销通路，由于勃起功能障碍发病率不断上升，促使人们寻求更快更有效的替代疗法，以及先进平台的不断涌现，在线药房已成为全球勃起功能障碍药物市场最重要的销售渠道。例如，致力于透过安全的远距医疗平台开发、行销和销售一系列男性健康产品的公司Mangoceuticals, Inc.，将于2023年10月透过其全新改版的网站推出联盟行销计画。该公司旗下品牌「Mango」专门研发治疗勃起功能障碍（ED）的药物。

勃起功能障碍市场—地理洞察

北美是治疗勃起功能障碍（ED）药物市场的重要收入来源地，这得益于ED的高发病率、先进的医疗基础设施以及广泛的患者教育。该地区拥有强大的研发能力，并聚集了辉瑞公司（威而钢）和礼来公司（希爱力）等领先的製药公司，这些公司不断透过新型配方和联合疗法进行创新。较高的可支配收入、更便利的医疗服务以及有利的报销机制都促进了市场的长期需求。然而，专利到期和仿製药的日益普及加剧了竞争，并影响了定价策略。根据牛津学术出版社（2024年2月）的数据，北美ED的平均盛行率为20.7%，且在各个年龄层以及伴随其他健康问题的人群中均呈现持续增长的趋势，凸显了该地区在临床和商业领域的持续重要性。

美国勃起功能障碍市场—国家概况

美国对北美勃起功能障碍药物市场贡献巨大。人口老化加剧、糖尿病和高血压等生活方式相关疾病的流行，以及人们对勃起功能障碍治疗方案日益增长的认知，都推动了市场成长。辉瑞和礼来等製药公司占有重要地位，透过包括零售药局和线上平台在内的多种分销管道，提供西地那非（威而钢）、他达拉非（希爱力）和伐地那非（艾力达）等药物。例如，2023年7月，Haleon公司透过与Futura公司达成商业化协议，进入美国非处方勃起功能障碍药物市场。 Futura公司研发的这款不含药物成分的MED3000凝胶近期获得了美国食品药物管理局（FDA）的批准，成为一种新型医疗器材。 Futura公司的这款外用製剂最初投入了400万美元用于商业化。

勃起功能障碍市场－竞争格局：

辉瑞公司、礼来公司、拜耳公司、Viatris公司、梯瓦製药工业有限公司和波士顿科学公司是治疗勃起功能障碍（ED）的主要市场参与者。这些公司正积极拓展产品线，在口服药物、阴茎植入物以及干细胞和衝击波疗法等新兴再生疗法方面不断创新。随着威而钢和希爱力等重磅药物的专利到期，仿製药和生物相似药得以进入市场，市场竞争日益激烈。此外，策略合作、併购以及远距医疗平台等数位医疗整合也在影响竞争格局。为了满足不断增长的全球患者群体的需求，创新、可及性和个人化治疗方案成为市场关注的重点。例如，2024年2月，Petros Pharmaceuticals和23andMe与一家大型人工智慧软体供应商合作，将先进技术融入其STENDRA（阿伐那非）非处方药批准的自我选择研究中。该人工智慧驱动的工具旨在提高筛检准确性，确保按照 FDA 和 ACNU 指南安全获取药物，并加快 Petros 获得非处方药资格的进程。

目录

第一章：勃起功能障碍市场概览

  • 研究范围
  • 市场估算年份

第二章：执行概要

  • 市集
    • 按应用分類的勃起功能障碍市场概览
    • 按治疗类型分類的勃起功能障碍市场概览
    • 按产品类型分類的勃起功能障碍市场概览
    • 按配销通路分類的勃起功能障碍市场概览
    • 各国勃起功能障碍市场概况
    • 按地区分類的勃起功能障碍市场概况
  • 竞争洞察

第三章：勃起功能障碍主要市场趋势

  • 勃起功能障碍市场驱动因素
    • 市场驱动因素的影响分析
  • 勃起功能障碍市场限制
    • 市场限制因素的影响分析
  • 勃起功能障碍市场机会
  • 勃起功能障碍市场未来趋势

第四章：勃起功能障碍产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景分析
  • 规范架构分析

第五章：勃起功能障碍市场：地缘政治紧张局势升级的影响

  • 新冠疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：勃起功能障碍市场概况

  • 2024年勃起功能障碍市占率分析
  • 主要製造商细分数据
    • 知名球员分析
    • 新兴参与者分析

第七章：勃起功能障碍市场－依应用领域划分

  • 概述
    • 按应用领域分類的细分市场占有率分析
    • 肠外
    • 口服

第八章：勃起功能障碍市场－依治疗类型划分

  • 概述
    • 按治疗类型分類的细分市场份额分析
    • 药物治疗
    • 器械疗法

第九章：勃起功能障碍市场－依产品类型划分

  • 概述
    • 按产品类型分類的细分市场占有率分析
    • 仿製药
      • 西地那非
      • 伐地那非
      • 前列地尔
      • 他达拉非
      • 其他的
    • 品牌药品
      • 希爱力
      • 齐德纳
      • 威而钢
      • 其他的

第十章：勃起功能障碍市场－依配销通路划分

  • 概述
    • 按治疗类型分類的细分市场份额分析
    • 医院药房
    • 网路药局
    • 零售药局

第十一章：勃起功能障碍市场－依地域划分

  • 介绍
    • 按地域分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美治疗勃起功能障碍的主要生产商
    • 北美市场规模及预测（按国家/地区划分）
    • 北美市场规模及预测（按应用划分）
    • 北美市场规模及预测（按治疗类型划分）
    • 北美市场规模及预测（依产品类型划分）
    • 北美市场规模及预测（按配销通路划分）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲治疗勃起功能障碍的主要生产者
    • 欧洲市场规模及预测（按国家/地区划分）
    • 欧洲市场规模及预测（按应用领域划分）
    • 欧洲市场规模及预测（依治疗类型划分）
    • 欧洲市场规模及预测（依产品类型划分）
    • 欧洲市场规模及预测（依配销通路划分）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区
    • 概述
    • 亚太地区治疗勃起功能障碍的主要生产者
    • 亚太市场规模及预测（依国家/地区划分）
    • 亚太市场规模及预测（按应用划分）
    • 亚太地区市场规模及预测（依治疗类型划分）
    • 亚太市场规模及预测（依产品类型划分）
    • 亚太市场规模及预测（按配销通路划分）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太其他地区
  • 拉丁美洲
    • 概述
    • 拉丁美洲治疗勃起功能障碍的主要生产商
    • 拉丁美洲市场规模及预测（按国家/地区划分）
    • 拉丁美洲市场规模及预测（按应用划分）
    • 拉丁美洲市场规模及预测（按治疗类型划分）
    • 拉丁美洲市场规模及预测（依产品类型划分）
    • 拉丁美洲市场规模及预测（按配销通路划分）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲（MEA）
    • 概述
    • 中东和非洲治疗勃起功能障碍的主要生产商
    • MEA市场规模及预测（依国家/地区划分）
    • MEA市场规模及预测（依应用划分）
    • MEA市场规模及预测（依治疗类型划分）
    • MEA市场规模及预测（依产品类型划分）
    • MEA市场规模及预测（依配销通路划分）
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • 中东和非洲其他地区

第十二章：主要供应商分析－勃起功能障碍产业

  • 竞争基准化分析
    • Competitive Dashboard
    • Competitive Positioning
  • 公司简介
    • Bayer AG
    • Lilly
    • Petros Pharmaceuticals, Inc.
    • Pfizer Inc.
    • GlaxoSmithKline PLC
    • Teva Pharmaceutical
    • Sanofi
    • Industries Ltd
    • Lupin Limited
    • Futura Medical
    • Cure Pharmaceutical
    • Sun Pharmaceutical Industries Ltd
    • VIVUS, Inc.
    • Auxilium Pharmaceuticals, Inc.
    • Others

第十三章：360度AnalystView

第十四章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV5766

Erectile Dysfunction Market size was valued at US$ 2,567.87 Million in 2024, expanding at a CAGR of 8.2% from 2025 to 2032.

Erectile dysfunction (ED) is defined as the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual activity. It is a multifactorial condition resulting from vascular, neurological, hormonal, or psychological causes that has a significant impact on men's physical and emotional health. The rising global prevalence of chronic diseases such as cardiovascular disorders and diabetes, both of which contribute significantly to ED, as well as sedentary lifestyles and stress-related conditions, is a key market driver. In contrast, the market is restrained by the loss of patent protection for blockbuster drugs such as Viagra and Cialis, which has resulted in price erosion and intense competition from generics. Nonetheless, an emerging opportunity is the development of next-generation oral therapies, stem-cell-based treatments, and digital health platforms that provide confidential online consultations and prescriptions. These innovations, combined with a growing acceptance of sexual wellness as part of men's health, are expected to drive the erectile dysfunction market's long-term growth and modernization.

Erectile Dysfunction Market- Market Dynamics

Rising Prevalence of Lifestyle-Related Diseases To Propel Growth In The Market

The increasing prevalence of lifestyle-related diseases is expected to fuel the erectile dysfunction market. Lifestyle-related diseases are health conditions that are primarily caused by unhealthy habits such as poor diet, lack of exercise, smoking, and binge drinking. The rise in lifestyle-related diseases is attributed to increased sedentary behavior, poor dietary habits, stress, and unhealthy habits such as smoking and excessive alcohol consumption. Erectile dysfunction (ED) is an early warning sign for lifestyle-related diseases such as cardiovascular disease and diabetes, emphasizing the importance of prompt medical attention and healthier lifestyle choices. For instance, according to a report published in May 2022 by the World Obesity Federation, a non-profit organization based in the United Kingdom, by 2030, one billion people worldwide, including one in every five women and one in every seven men, are expected to be obese, rising to 4 billion people, or 51% of the global population, by 2035. As a result, the increasing prevalence of lifestyle-related diseases will drive growth in the erectile dysfunction industry.

Erectile Dysfunction Market- Segmentation Analysis:

The Global Erectile Dysfunction Market is segmented by Application, Therapy Type, Product Type, Distribution Channel and Region.

According to the Application, Oral medication is the highest revenue-generating segment in the global erectile dysfunction drugs market in 2025, owing to an increase in the use of oral medications such as Cialis, Stendra, Viagra, and others, which can be self-administered and are cost-effective, as well as increasing partnerships and collaborations among market players. For instance, in May 2022, Laboratorios Rubio S.A. sold the prescription medication BANDOL (sildenafil oral suspension) to Aspargo Laboratories, Inc. BANDOL is used to treat erectile dysfunction. Concurrently with this acquisition, Aspargo signed a distribution agreement with Rubio to continue marketing and promoting BANDOL in the Spanish market.

By Distribution Channel, Online pharmacies are the most important selling channel in the global erectile dysfunction drugs market, owing to the rising incidence of erectile dysfunction, which is driving the adoption of alternative treatments for faster and more effective results, as well as the increased launch of advanced platforms. For example, in October 2023, Mangoceuticals, Inc., a company dedicated to the development, marketing, and sale of a range of men's health and wellness products through a secure telemedicine platform, including its specially formulated erectile dysfunction (ED) medication under the brand name "Mango," will launch its affiliate marketing program via its newly revamped website.

Erectile Dysfunction Market- Geographical Insights

North America is a significant revenue-generating region in the erectile dysfunction (ED) drugs market, thanks to a high prevalence of ED, advanced healthcare infrastructure, and widespread patient education. The region benefits from strong R&D capabilities as well as the presence of leading pharmaceutical companies like Pfizer Inc. (Viagra) and Eli Lilly and Company (Cialis), which are constantly innovating through novel formulations and combination therapies. High disposable incomes, improved access to healthcare, and favorable reimbursement frameworks all contribute to long-term market demand. However, patent expirations and the increasing availability of generic alternatives have increased competition and influenced pricing strategies. According to Oxford Academic (February 2024), the average ED prevalence rate in North America was 20.7%, with a steady increase observed across age groups and among individuals with associated health comorbidities, highlighting the region's continued clinical and commercial importance.

United States Erectile Dysfunction Market- Country Insights

The United States makes a significant contribution to the North American erectile dysfunction drug market. A large aging population, lifestyle-related diseases such as diabetes and hypertension, and rising awareness of erectile dysfunction treatment options all contribute to market growth. Pharmaceutical companies such as Pfizer and Eli Lilly have a significant presence, providing medications such as sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra) through a variety of distribution channels, including retail pharmacies and online platforms. For example, in July 2023, Haleon entered the US OTC erectile dysfunction market with a commercialization agreement for Futura's drug-free MED3000 gel, which was recently approved by the FDA as a de novo medical device. Futura's topical treatment, which was recently approved by the US Food and Drug Administration as an over-the-counter medical device, cost $4 million to commercialize initially.

Erectile Dysfunction Market- Competitive Landscape:

Pfizer Inc., Eli Lilly and Company, Bayer AG, Viatris Inc., Teva Pharmaceutical Industries Ltd., and Boston Scientific Corporation are among the top Erectile Dysfunction (ED) market players. These companies are actively diversifying their product offerings with innovations in oral medications, penile implants, and emerging regenerative therapies like stem cell and shockwave treatments. The market is experiencing increased competition as patents for blockbuster drugs such as Viagra and Cialis expire, allowing generics and biosimilars to enter the marketplace. In addition, strategic collaborations, mergers, and digital health integrations such as telemedicine platforms for prescription and consultation are influencing competitive dynamics. To meet the needs of a growing global patient base, the landscape prioritizes innovation, accessibility, and personalized treatment options. For instance, in February 2024, Petros Pharmaceuticals and 23andMe collaborated with a major AI software provider to incorporate advanced technology into its Self-Selection Study for STENDRA (avanafil) OTC approval. The AI-driven tool aimed to improve screening accuracy, ensure safe medication access in accordance with FDA and ACNU guidelines, and accelerate Petros' path to OTC status.

Recent Developments:

In March 2024, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved OPSYNVI, a single-tablet combination of macitentan, an endothelin receptor antagonist (ERA), and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, for the chronic treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group I) and WHO functional class II-III.1 OPSYNVI(R) can be used for PAH patients who are treatment-naive or already taking an ERA, PDE5 inhibitor, or both.

In July 2024, Aspargo Labs, Inc., a speciality pharmaceutical and MedTech company focused on transforming drug delivery through innovative oral sprays, today announced the release of a Phase 1 study demonstrating that ASP-001, an investigative sildenafil oral spray in development for erectile dysfunction (ED), achieves absorption within five minutes, which is twice as fast as traditional sildenafil tablets.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as following:

GLOBAL ERECTILE DYSFUNCTION MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Bayer AG
  • Lilly
  • Petros Pharmaceuticals, Inc.
  • Pfizer Inc.
  • GlaxoSmithKline PLC
  • Teva Pharmaceutical
  • Sanofi
  • Industries Ltd
  • Lupin Limited
  • Futura Medical
  • Cure Pharmaceutical
  • Sun Pharmaceutical Industries Ltd
  • VIVUS, Inc.
  • Auxilium Pharmaceuticals, Inc.
  • Others

GLOBAL ERECTILE DYSFUNCTION MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Parenteral
  • Oral

GLOBAL ERECTILE DYSFUNCTION MARKET, BY THERAPY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Drug Therapy
  • Device Therapy

GLOBAL ERECTILE DYSFUNCTION MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Generic Drugs
  • Sildenafil
  • Vardenafil
  • Alprostadil
  • Tadalafil
  • Others
  • Branded Drugs
  • Cialis
  • Zydena
  • Viagra
  • Others

GLOBAL ERECTILE DYSFUNCTION MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

GLOBAL ERECTILE DYSFUNCTION MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Erectile Dysfunction Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Erectile Dysfunction Market Snippet by Application
    • 2.1.2. Erectile Dysfunction Market Snippet by Therapy Type
    • 2.1.3. Erectile Dysfunction Market Snippet by Product Type
    • 2.1.4. Erectile Dysfunction Market Snippet by Distribution Channel
    • 2.1.5. Erectile Dysfunction Market Snippet by Country
    • 2.1.6. Erectile Dysfunction Market Snippet by Region
  • 2.2. Competitive Insights

3. Erectile Dysfunction Key Market Trends

  • 3.1. Erectile Dysfunction Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Erectile Dysfunction Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Erectile Dysfunction Market Opportunities
  • 3.4. Erectile Dysfunction Market Future Trends

4. Erectile Dysfunction Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Erectile Dysfunction Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Erectile Dysfunction Market Landscape

  • 6.1. Erectile Dysfunction Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Erectile Dysfunction Market - By Application

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 7.1.2. Parenteral
    • 7.1.3. Oral

8. Erectile Dysfunction Market - By Therapy Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Therapy Type, 2024 & 2032 (%)
    • 8.1.2. Drug Therapy
    • 8.1.3. Device Therapy

9. Erectile Dysfunction Market - By Product Type

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Product Type, 2024 & 2032 (%)
    • 9.1.2. Generic Drugs
      • 9.1.2.1. Sildenafil
      • 9.1.2.2. Vardenafil
      • 9.1.2.3. Alprostadil
      • 9.1.2.4. Tadalafil
      • 9.1.2.5. Others
    • 9.1.3. Branded Drugs
      • 9.1.3.1. Cialis
      • 9.1.3.2. Zydena
      • 9.1.3.3. Viagra
      • 9.1.3.4. Others

10. Erectile Dysfunction Market - By Distribution Channel

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Therapy Type, 2024 & 2032 (%)
    • 10.1.2. Hospital Pharmacies
    • 10.1.3. Online Pharmacies
    • 10.1.4. Retail Pharmacies

11. Erectile Dysfunction Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Erectile Dysfunction Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Erectile Dysfunction Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Erectile Dysfunction Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Erectile Dysfunction Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Erectile Dysfunction Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Therapy Type, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Erectile Dysfunction Industry

  • 12.1. Competitive Benchmarking
    • 12.1.1. Competitive Dashboard
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Bayer AG
    • 12.2.2. Lilly
    • 12.2.3. Petros Pharmaceuticals, Inc.
    • 12.2.4. Pfizer Inc.
    • 12.2.5. GlaxoSmithKline PLC
    • 12.2.6. Teva Pharmaceutical
    • 12.2.7. Sanofi
    • 12.2.8. Industries Ltd
    • 12.2.9. Lupin Limited
    • 12.2.10. Futura Medical
    • 12.2.11. Cure Pharmaceutical
    • 12.2.12. Sun Pharmaceutical Industries Ltd
    • 12.2.13. VIVUS, Inc.
    • 12.2.14. Auxilium Pharmaceuticals, Inc.
    • 12.2.15. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us